Aug 10,2023

Kakao Healthcare partners with Novo Nordisk for digital diabetes service

Kakao Healthcare, the digital healthcare business of South Korean internet company Kakao Corporation, has partnered with Novo Nordisk to further develop its diabetes management service powered by mobile and AI technologies. According to a press release, Kakao Healthcare's digital diabetes management service, Project Gamma, will feature the French medical device company BIOCORP's Mallya smart sensor, which Novo Nordisk plans to release in South Korea some time this year. Its collaboration with Novo Nordisk followed its recent signing of a global partnership with Dexcom to set up a diabetes management service starting in South Korea later this year.

COLLABORATION PARTNERSHIP

#connected device

#insulin pen

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 10,2023

Ultrahuman Ring Air review

Indian fitness and nutrition tracking startup Ultrahuman has fast-followed its debut smart ring last year with a second generation of the device — which officially launched in June. Ultrahuman’s smart ring is designed to sit alongside its CGM-powered program; either as a standalone sleep & fitness tracker (with the bonus ability to dish some dietary insights, if you log what you’re eating in the companion app, powered by aggregated data from a metabolic health tracking program called Cyborg users); or as a complement to the fully fledged metabolic health tracking program.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 02,2023

British Columbia expands public coverage of type 1 diabetes technologies to include a flash glucose monitoring device

The Government of British Columbia announced yesterday that the FreeStyle Libre, a flash glucose monitoring (Flash GM) device, will be covered by BC PharmaCare as a limited-coverage benefit for people living with type 1 diabetes (T1D) beginning August 1st 2023. Prior to this announcement, public coverage in British Columbia was limited to only the Dexcom G6 continuous glucose monitor (CGM). In British Columbia, it is estimated that 34,000 people live with T1D. Use of devices like Flash GMs have been shown to reduce hospitalizations and the risk of longer-term complications for its users. Through its #AccessForAll advocacy campaign, JDRF Canada has been working to help make a variety of T1D technologies affordable and accessible for all Canadians living with the disease.

PRODUCT

#reimbursement

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 28,2023

Real-World Evidence of the Cambridge Hybrid Closed-Loop App With a Novel Real-Time Continuous Glucose Monitoring System

The study evaluated the performance of the interoperable Cambridge hybrid closed-loop app with FreeStyle Libre 3 glucose sensor, and YpsoPump insulin pump in a real-world setting. Data from 100 users (63 adults, 15 children] and 22 users of unreported age) for a period of 28 days were analyzed. Time in range (3.91- 10.0mmol/L) was 72.6 ± 11.1% overall. Time below range (<3.9mmol/L) was 3.1%. Auto-mode was active for 95.8% of time. This real-world analysis suggested that the performance of Cambridge hybrid closed-loop app with this glucose sensor is comparable to other commercially available hybrid closed-loop systems.

CLINICAL STUDY

#closed loop

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 12,2023

Association of Smartphone-Based Activity Tracking and Nocturnal Hypoglycemia in People With Type 1 Diabetes

Nocturnal hypoglycemia (NH) remains a major burden for people with type 1 diabetes (T1D). Daytime physical activity (PA) increases the risk of NH. This pilot study tested whether cumulative daytime PA measured using a smartphone-based step tracker was associated with NH. Adults with T1D for ≥ 5 years (y) on multiple daily insulin or continuous insulin infusion, not using continuous glucose monitoring and HbA1c 6 to 10% wore blinded Freestyle Libre Pro sensors and recorded total daily carbohydrate (TDC) and total daily dose (TDD) of insulin. During this time, daily step count (DSC) was tracked using the smartphone-based Fitbit MobileTrack application. The results suggested that daily PA measured by a smartphone-based step tracker was associated with the risk of NH in people with type 1 diabetes.

CLINICAL STUDY

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 14,2023

Prolonged Use of an Automated Insulin Delivery System Improves Sleep in Long-Standing Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia

This study assessed changes in actigraphy-estimated sleep and glycemic outcomes after initiating automated insulin delivery (AID) Minimed 670G system. Ten adults with long-standing type 1 diabetes and impaired awareness of hypoglycemia (IAH) participated in an 18-month clinical trial assessing an AID intervention on hypoglycemia and counter-regulatory mechanisms. Data from eight participants (median age = 58 years) with concurrent wrist actigraph and continuous glucose monitoring (CGM) data were used in the present analyses. Sleep improvements were evident from 12 to 15 months after AID initiation and were preceded by improved hypoglycemia awareness , reduced hypoglycemia severity, reduced sleep-associated hypoglycemia, and reduced glucose variability.

CLINICAL STUDY

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 27,2023

Treatment Satisfaction and Well-Being With CGM in People With T1D: An Analysis Based on the GOLD Randomized Trial

The GOLD trial was a randomized crossover trial comparing CGM versus self-monitored blood glucose (SMBG) over 16 months. Endpoints included well-being measured by the World Health Organization–Five Well-Being Index (WHO-5) and treatment satisfaction by the Diabetes Treatment Satisfaction Questionnaire (DTSQ) as well as glucose metrics. A total of 139 participants were included. The GOLD trial demonstrated that continuous glucose monitoring (CGM) in people with type 1 diabetes (T1D) managed with multiple daily insulin injections (MDI) improved not only glucose control but also overall well-being and treatment satisfaction.

CLINICAL STUDY

#cgm

#bgm

View Analyst & Ambassador Comments
Go to original news
Jul 25,2023

GLUCOTRACK ANNOUNCES POSITIVE DATA FROM FEASIBILITY STUDY FOR IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Glucotrack, a medical device and digital health platform company focused on diabetes and prediabetes, announced today the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes. The primary goal of the feasibility study was to demonstrate that the CGM sensor design could reliably report glucose measurements for two years post-implant. Laboratory bench testing confirmed that a minimum two-year implant longevity is highly probable with the current sensor design. The implant longevity was independently verified by a third-party using sensor parameters to simulate sensor performance over time. Given the positive results of the study, the Company is now preparing for long-term animal studies, which are expected to begin later this year.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 20,2023

FDA clears automated insulin pump from Beta Bionics for type 1 diabetes

The FDA has cleared the Beta Bionics iLet ACE automated insulin pump and iLet dosing decision software for people aged 6 and above with type 1 diabetes. The iLet Bionic Pancreas, which pairs with Dexcom G6 CGM, uses an adaptive, closed-loop algorithm to determine and command insulin delivery, simplifying diabetes management. The system showed promising results in reducing HbA1c and improving the quality of life in trial participants. The company hopes the iLet will alleviate the burden of diabetes management and be a step towards a fully automated insulin dosing system.

REGULATORY FDA

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 13,2023

Swimming With the Omnipod 5 Automated Insulin Delivery System: Connectivity in the Water

Swimming poses additional challenges for glycemic management with continuous glucose monitoring (CGM) and AID devices. The Omnipod 5 Automated Insulin Delivery System addresses this with a waterproof “Pod”. In the Omnipod 5 pivotal trial, some participants reported continued system function in the water. To investigate in-water system functionality, a single-center observational substudy was conducted from September 2021 until April 2022 among individuals in the Omnipod 5 pivotal extension study at Stanford University. The survey collected information related to swims, including measured interdevice distance and device placement on the body. On-body testing showed that communication success rates dropped off quickly with interdevice distances >13 cm. However, improved connectivity does not fully address glycemic control, which is also influenced by initial glucose at exercise start, circulating insulin levels, carbohydrate intake, and exercise intensity.

CLINICAL STUDY

#closed loop

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM